New weekly shot aims to prevent bleeding in hemophilia patients

NCT ID NCT07545395

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 study is testing a drug called KN057, given as a weekly injection under the skin, to prevent bleeding in people with hemophilia A or B (with or without inhibitors). The trial will enroll 70 males aged 12 to 65 and will monitor safety and how well the drug works over 52 weeks. Some participants will also compare two different manufacturing processes of the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
KN057 (a drug given as a weekly injection under the skin)
What this could lead to
If successful, this could provide a new, convenient once-weekly preventive treatment to reduce bleeding episodes in people with hemophilia A or B, including those with inhibitors.
What could go wrong
This is a Phase 3 trial, but it is still early to know if KN057 works better than existing options. Potential risks include allergic reactions, injection site issues, and rare but serious blood clotting events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A OR B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences

    RECRUITING

    Tianjin, Tianjin Municipality, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.